Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Capital Expenditures (2020 - 2025)

Historic Capital Expenditures for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $148000.0.

  • Apellis Pharmaceuticals' Capital Expenditures changed N/A to $148000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $225000.0, marking a year-over-year decrease of 5292.89%. This contributed to the annual value of $403000.0 for FY2024, which is 4786.55% down from last year.
  • Apellis Pharmaceuticals' Capital Expenditures amounted to $148000.0 in Q3 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Capital Expenditures ranged from a high of $851000.0 in Q4 2022 and a low of $8000.0 during Q1 2025
  • Its 5-year average for Capital Expenditures is $222666.7, with a median of $172000.0 in 2022.
  • Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 9732.77% in 2021, then skyrocketed by 437894.74% in 2022.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Capital Expenditures stood at $19000.0 in 2021, then surged by 4378.95% to $851000.0 in 2022, then tumbled by 88.84% to $95000.0 in 2023, then crashed by 78.95% to $20000.0 in 2024, then soared by 640.0% to $148000.0 in 2025.
  • Its last three reported values are $148000.0 in Q3 2025, $49000.0 for Q2 2025, and $8000.0 during Q1 2025.